País: Estados Unidos
Idioma: inglés
Fuente: NLM (National Library of Medicine)
POTASSIUM CITRATE (UNII: EE90ONI6FF) (ANHYDROUS CITRIC ACID - UNII:XF417D3PSL)
PD-Rx Pharmaceuticals, Inc.
ORAL
PRESCRIPTION DRUG
Potassium citrate is indicated for the management of renal tubular acidosis [see Clinical Studies (14.1)]. Potassium citrate is indicated for the management of Hypocitraturic calcium oxalate nephrolithiasis [see Clinical Studies (14.2)]. Potassium citrate is indicated for the management of Uric acid lithiasis with or without calcium stones [see Clinical Studies (14.3)]. Potassium citrate extended-release tablets is contraindicated: - In patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). - In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. - In patients with peptic ulcer disease because of its ulcerogenic potential. - In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of potassium citrate extended-release tablet to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate extended-release tablet therapy might promote further bacterial growth. - In patients with renal insufficiency (glomerular filtration rate of less than 0.7 ml/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. Animal reproduction studies have not been conducted. It is also not known whether potassium citrate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Potassium citrate should be given to a pregnant woman only if clearly needed. The normal potassium ion content of human milk is about 13 mEq/L. It is not known if potassium citrate has an effect on this content. Potassium citrate should be given to a woman who is breast feeding only if clearly needed. Safety and effectiveness in children have not been established.
Potassium Citrate Extended-release Tablets USP, 5 mEq tablets are uncoated, tan to yellowish speckled in color, round shaped, with E34 debossed on one side and plain on the other side, supplied in bottles as: NDC 72789-202-30 Bottle of 30 NDC 72789-202-01 Bottle of 100 Potassium Citrate Extended-release Tablets USP, 10 mEq tablets are uncoated, tan to yellowish speckled in color, elliptical shaped, with E35 debossed on one side and plain on the other side, supplied in bottles as: NDC 72789-203-30 Bottle of 30 NDC 72789-203-01 Bottle of 100 Potassium Citrate Extended-release Tablets, USP 15 mEq tablets are uncoated, tan to yellowish speckled in color, modified rectangle shaped, with E36 debossed on one side and plain on the other side, supplied in bottles as: NDC 72789-204-30 Bottle of 30 NDC 72789-204-01 Bottle of 100 Storage: Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Store in a tight container. Unit-of-use package. Dispense in this container without repackaging.
Abbreviated New Drug Application
POTASSIUM CITRATE- POTASSIUM CITRATE TABLET, EXTENDED RELEASE PD-RX PHARMACEUTICALS, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE POTASSIUM CITRATE EXTENDED-RELEASE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR POTASSIUM CITRATE EXTENDED-RELEASE TABLETS. POTASSIUM CITRATE EXTENDED- RELEASE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1985 INDICATIONS AND USAGE Potassium citrate extended-release tablets is a citrate salt of potassium indicated for the management of: (1) Renal tubular acidosis (RTA) with calcium stones (1.1) Hypocitraturic calcium oxalate nephrolithiasis of any etiology (1.2) Uric acid lithiasis with or without calcium stones (1.3) DOSAGE AND ADMINISTRATION Objective: To restore normal urinary citrate (greater than 320 mg/day and as close to the normal mean of 640 mg/day as possible), and to increase urinary pH to a level of 6.0 to 7.0. (2) Severe hypocitraturia (urinary citrate < 150 mg/day): therapy should be initiated at 60 mEq per day; a dose of 30 mEq two times per day or 20 mEq three times per day with meals or within 30 minutes after meals or bedtime snack (2.2) Mild to moderate hypocitraturia (urinary citrate >150 mg/day): therapy should be initiated at 30 mEq per day; a dose of 15 mEq two times per day or 10 mEq three times per day with meals or within 30 minutes after meals or bedtime snack (2.3) DOSAGE FORMS AND STRENGTHS Tablets: 5 mEq, 10 mEq and 15 mEq (3) CONTRAINDICATIONS Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown (4) Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture (4) Pa Leer el documento completo